12 Health Care Stocks Moving In Monday's Intraday Session

Benzinga · 5d ago
Gainers
- Lyra Therapeutics (NASDAQ:LYRA) stock rose 376.8% to $23.5 during Monday's regular session. The market value of their outstanding shares is at $31.1 million.
- Vera Therapeutics (NASDAQ:VERA) stock increased by 64.08% to $31.09. The company's market cap stands at $1.9 billion.
- ModivCare (NASDAQ:MODV) stock rose 59.82% to $1.79. The company's market cap stands at $25.6 million.
- Hyperfine (NASDAQ:HYPR) shares rose 58.0% to $0.95. The company's market cap stands at $74.1 million.
- Processa Pharmaceuticals (NASDAQ:PCSA) stock moved upwards by 56.58% to $0.46. The company's market cap stands at $5.4 million.
- Plus Therapeutics (NASDAQ:PSTV) shares moved upwards by 40.92% to $0.4. The company's market cap stands at $2.3 million. The company's, Q1 earnings came out yesterday.
Losers
- Xilio Therapeutics (NASDAQ:XLO) stock declined by 31.2% to $0.74 during Monday's regular session. The company's market cap stands at $38.1 million.
- Basel Medical Group (NASDAQ:BMGL) stock declined by 27.47% to $4.41. The company's market cap stands at $82.8 million.
- BioLine Rx (NASDAQ:BLRX) shares fell 19.24% to $4.24. The market value of their outstanding shares is at $15.7 million. The company's, Q1 earnings came out 4 days ago.
- Verastem (NASDAQ:VSTM) shares decreased by 18.82% to $6.11. The company's market cap stands at $335.4 million.
- TherapeuticsMD (NASDAQ:TXMD) stock declined by 17.81% to $1.2. The market value of their outstanding shares is at $13.8 million.
- Olema Pharmaceuticals (NASDAQ:OLMA) stock fell 16.1% to $4.43. The market value of their outstanding shares is at $303.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.